Not all Patients with Severe/Critical COVID-19 Pneumonia Benefit from Tocilizumab

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Prospective study identifies serum IL-6 levels affecting mortality in COVID-19 pneumonia patients, highlighting treatment adjustments.

Serum IL-6 levels ≥60.28 pg/ml predict in-hospital mortality, revealing an important threshold for intervention.
Study involved 88 patients with severe COVID-19 pneumonia, of which 28.41% died during hospitalization.
Prospective longitudinal study conducted in Peshawar, Pakistan, assessing treatment outcomes with Tocilizumab.
Findings suggest that Tocilizumab may not benefit patients with excessively high IL-6 levels, indicating need for caution.

Arshad et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark